Global pharmaceutical major Lupin announced the launch of an authorized generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1 g/mL, in theUnited States.

The product is indicated for the chronic management of patients with Urea Cycle Disorders (UCDs) who cannot be adequately managed through dietary protein restriction and/or amino acid supplementation alone.

With this launch, Lupin continues to expand its portfolio of specialty and generic products in the U.S. market, reinforcing its commitment to improving patient access to high-quality, affordable treatments.